biocrea, Boehringer Ingelheim deal

Boehringer acquired biocrea's phosphodiesterase-2 (PDE-2) program. The program's lead compound is BCA909, a PDE-2 inhibitor in preclinical testing for mild cognitive impairment and Alzheimer's disea...